Literature DB >> 26595180

Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

Chadwan Al Yaghchi1, Zhongxian Zhang2, Ghassan Alusi1, Nicholas R Lemoine1,2, Yaohe Wang1,2.   

Abstract

The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effects by multiple action mechanisms. Vaccinia virus has several inherent features that make it particularly suitable for use as an oncolytic agent. In this review, we will discuss the potential of vaccinia virus in the management of pancreatic cancer in light of our increased understanding of cellular and immunological mechanisms involved in the disease process as well as our extending knowledge in the biology of vaccinia virus.

Entities:  

Keywords:  immunotherapy; oncolytic virus; pancreatic cancer; vaccinia virus

Mesh：

Substances：

Year:  2015        PMID： 26595180      PMCID： PMC4976866          DOI： 10.2217/imt.15.90

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  119 in total

1.  Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines.

Authors:  M-H Dai; D Zamarin; S P Gao; T-C Chou; L Gonzalez; S-F Lin; Y Fong
Journal:  Br J Surg       Date:  2010-09       Impact factor: 6.939

Review 2.  Oncolytic viruses for induction of anti-tumor immunity.

Authors:  Alex W Tong; Neil Senzer; Vincenzo Cerullo; Nancy Smyth Templeton; Akseli Hemminki; John Nemunaitis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

3.  Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.

Authors:  Ilkka Liikanen; Laura Ahtiainen; Mari L M Hirvinen; Simona Bramante; Vincenzo Cerullo; Petri Nokisalmi; Otto Hemminki; Iulia Diaconu; Sari Pesonen; Anniina Koski; Lotta Kangasniemi; Saila K Pesonen; Minna Oksanen; Leena Laasonen; Kaarina Partanen; Timo Joensuu; Fang Zhao; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2013-04-02       Impact factor: 11.454

4.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.

Authors:  Hidenobu Ishizaki; Edwin R Manuel; Guang-Yun Song; Tumul Srivastava; Sabrina Sun; Don J Diamond; Joshua D I Ellenhorn
Journal:  Cancer Immunol Immunother       Date:  2010-10-20       Impact factor: 6.968

Review 6.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

Review 7.  Vaccinia virus transcription.

Authors:  Steven S Broyles
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

8.  The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

Authors:  Ta-Chiang Liu; Taeho Hwang; Byeong-Ho Park; John Bell; David H Kirn
Journal:  Mol Ther       Date:  2008-07-15       Impact factor: 11.454

9.  Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.

Authors:  Enrique Miranda; Hector Maya Pineda; Daniel Öberg; Gioia Cherubini; Zita Garate; Nick R Lemoine; Gunnel Halldén
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

10.  Systemic delivery of oncolytic viruses: hopes and hurdles.

Authors:  Mark S Ferguson; Nicholas R Lemoine; Yaohe Wang
Journal:  Adv Virol       Date:  2012-01-31
View more
  24 in total

Review 1.  Virotherapy: cancer gene therapy at last?

Authors:  Alan E Bilsland; Pavlina Spiliopoulou; T R Jeffry Evans
Journal:  F1000Res       Date:  2016-08-30

2.  New p35 (H3L) Epitope Involved in Vaccinia Virus Neutralization and Its Deimmunization.

Authors:  Yana Khlusevich; Andrey Matveev; Lyudmila Emelyanova; Elena Goncharova; Natalia Golosova; Ivan Pereverzev; Nina Tikunova
Journal:  Viruses       Date:  2022-06-05       Impact factor: 5.818

3.  MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage.

Authors:  Ethan Laudermilch; Kartik Chandran
Journal:  J Mol Biol       Date:  2021-02-24       Impact factor: 5.469

4.  Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.

Authors:  Elena P Goncharova; Julia S Ruzhenkova; Ivan S Petrov; Sergey N Shchelkunov; Marina A Zenkova
Journal:  J Transl Med       Date:  2016-08-18       Impact factor: 5.531

Review 5.  Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer.

Authors:  Anwen Howells; Giulia Marelli; Nicholas R Lemoine; Yaohe Wang
Journal:  Front Oncol       Date:  2017-09-08       Impact factor: 6.244

6.  ING4 expressing oncolytic vaccinia virus promotes anti-tumor efficiency and synergizes with gemcitabine in pancreatic cancer.

Authors:  Yinfang Wu; Xiaozhou Mou; Shibing Wang; Xing-E Liu; Xiaodong Sun
Journal:  Oncotarget       Date:  2017-09-20

Review 7.  Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors.

Authors:  Maider Varela-Guruceaga; Sonia Tejada-Solís; Marc García-Moure; Juan Fueyo; Candelaria Gomez-Manzano; Ana Patiño-García; Marta M Alonso
Journal:  Cancers (Basel)       Date:  2018-07-09       Impact factor: 6.639

Review 8.  Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors.

Authors:  Sally Al Ali; Sara Baldanta; Mercedes Fernández-Escobar; Susana Guerra
Journal:  Viruses       Date:  2016-05-21       Impact factor: 5.048

9.  Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose.

Authors:  Michael P O'Leary; Audrey H Choi; Sang-In Kim; Shyambabu Chaurasiya; Jianming Lu; Anthony K Park; Yanghee Woo; Susanne G Warner; Yuman Fong; Nanhai G Chen
Journal:  J Transl Med       Date:  2018-04-26       Impact factor: 5.531

10.  Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.

Authors:  Mark S Ferguson; Louisa S Chard Dunmall; Rathi Gangeswaran; Giulia Marelli; James R Tysome; Emily Burns; Maria A Whitehead; Ezra Aksoy; Ghassan Alusi; Crispin Hiley; Jay Ahmed; Bart Vanhaesebroeck; Nicholas R Lemoine; Yaohe Wang
Journal:  Mol Ther       Date:  2020-02-28       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.